Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft in AV Graft Patients (AVeVA)

NACompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

March 16, 2019

Conditions
StenosisRestenosis
Interventions
DEVICE

Covera(TM) Vascular Covered Stent

Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.

Trial Locations (16)

27607

NC Heart and Vascular Research, Raleigh

27610

NC Nephrology, Raleigh

28207

Surgical Specialists of Charlotte, Charlotte

32207

Jacksonville Center for Clinical Research, Jacksonville

34471

Ocala Kidney Group, Ocala

60521

Chicago Access Care, Chicago

76104

Tarrant Vascular Clinic, Fort Worth

78215

Clinical Advancement Center, PLLC, San Antonio

85012

Arizona Kidney Disease and Hypertension Center, Phoenix

85281

Southwest Vascular Center, Tempe

85712

Arizona Kidney Disease and Hypertension Center Medical Research Services, LLC, Tucson

92868

St. Joseph Hospital, Orange

95815

Capital Nephrology Access Center, Sacramento

01089

Renal and Transplant Associates of New England, P.C., West Springfield

07090

The Cardiovascular Care Group, Westfield

02906

Providence Access Care, Providence

Sponsors

Lead Sponsor

All Listed Sponsors
lead

C. R. Bard

INDUSTRY

NCT02790606 - Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft in AV Graft Patients (AVeVA) | Biotech Hunter | Biotech Hunter